基于扩散大B细胞淋巴瘤瘤免疫微环境的代谢重塑,优化CAR-T疗法
Lijuan Yuan1, Chunxiao Wang1, Lifa Du1
1Hematological Department, People's Hospital of Rizhao No. 126, Tai'an Road, Donggang District, Rizhao 276827, Shandong, China.
American journal of cancer research
|September 15, 2025
概括
卡特-T疗法对复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 有希望. 针对瘤的微环境.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 具有复发/耐药病例和有限的治疗选择的挑战.
- 像R-CHOP这样的当前疗法在先进的DLBCL中有效性受到限制.
- 化学抗原受体T细胞 (CAR-T) 疗法具有潜力,但面临着局限性.
研究的目的:
- 研究瘤微环境 (TME) 在限制DLBCL的CAR-T治疗疗效方面的作用.
- 探索TME内的代谢重编程作为提高CAR-T治疗结果的目标.
- 确定在TME中克服免疫抑制和代谢竞争的战略.
主要方法:
- 在DLBCL TME中分析免疫抑制因素和代谢竞争.
- 研究TME代谢状态 (如低葡萄糖) 对CAR-T细胞功能的影响.
- 审查代谢干预和CAR-T协同作用的战略.
主要成果:
- TME通过免疫抑制和代谢竞争来抑制CAR-T细胞功能.
- 代谢重编程是连接瘤和免疫细胞的关键机制.
- 在TME中低葡萄糖可以损害CAR-T细胞增殖和细胞毒性,尽管激活了糖解.
结论:
- 准TME代谢重塑对于增强DLBCL中的CAR-T疗法至关重要.
- 涉及代谢调节剂和CAR-T细胞的组合策略具有显著的治疗前景.
- 需要进一步研究代谢重编程机制和药物的临床转化.
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


